Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04294017
Other study ID # 1496/2017
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 1, 2017
Est. completion date December 31, 2022

Study information

Verified date February 2021
Source Medical University of Vienna
Contact Lorenz Kuessel, Dr.
Phone +4314040049160
Email lorenz.kuessel@meduniwien.ac.at
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Background: Endometriosis, which is characterized by the growth of endometrial stroma and glands outside of the uterine cavity, is estimated to occur in 6-10% of women of reproductive age. Clinical presentation of endometriosis can vary widely, often significantly reducing quality of life, and the mean interval between the onset of symptoms and obtaining a definitive diagnosis is approximately 10 years. Currently, laparoscopy is the gold standard for diagnosing endometriosis; however, this procedure is invasive, carries surgery-related risks, and contributes to diagnostic delay. Therefore, the field has an urgent need for an efficient, sensitive, non-invasive tool for diagnosing endometriosis. Recently, it was shown that sVCAM-1/sICAM-1 ratio is a promising serum biomarker, which may lead to the development of a new, efficient, sensitive, non-invasive tool for diagnosing endometriosis, thereby potentially avoiding surgical interventions. Primary aim: To determine whether the serum sVCAM-1/sICAM-1 ratio can be used todiagnose endometriosis. Study design: Prospective multicenter validation study


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date December 31, 2022
Est. primary completion date June 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - unfulfilled desire for children - chronic pelvic pain - suspicion of endometriosis - cysts - myomas Exclusion Criteria: - acute infections - malign diseases - drug abuse - pregnancy - infectious diseases

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Austria Medical University Vienna Vienna

Sponsors (2)

Lead Sponsor Collaborator
Heinrich Husslein Medical-Scientific Fund of the Mayor of the Federal Capital Vienna

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Primary sICAM and sVCAM in serum levels of these two soluble adhesion factors in serum of patients and controls up to 1 week
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05523284 - Combining Ultrasound and Biomarkers to Diagnose Superficial Endometriosis
Recruiting NCT03376451 - EndoSearch : Endometriosis Biomarkers N/A